RU2017106945A - Пептиды, применимые для лечения злокачественной опухоли - Google Patents
Пептиды, применимые для лечения злокачественной опухоли Download PDFInfo
- Publication number
- RU2017106945A RU2017106945A RU2017106945A RU2017106945A RU2017106945A RU 2017106945 A RU2017106945 A RU 2017106945A RU 2017106945 A RU2017106945 A RU 2017106945A RU 2017106945 A RU2017106945 A RU 2017106945A RU 2017106945 A RU2017106945 A RU 2017106945A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- pro
- paragraphs
- arg
- malignant tumor
- Prior art date
Links
- 201000011510 cancer Diseases 0.000 title claims 40
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 140
- 125000000539 amino acid group Chemical group 0.000 claims 40
- 150000001923 cyclic compounds Chemical class 0.000 claims 30
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 25
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 claims 25
- 238000000034 method Methods 0.000 claims 24
- 101001113483 Homo sapiens Poly [ADP-ribose] polymerase 1 Proteins 0.000 claims 23
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 239000003814 drug Substances 0.000 claims 21
- 239000003112 inhibitor Substances 0.000 claims 17
- 230000006536 aerobic glycolysis Effects 0.000 claims 16
- -1 1,2-dihydronaphthyl group Chemical group 0.000 claims 15
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims 14
- 102100034671 L-lactate dehydrogenase A chain Human genes 0.000 claims 13
- 108010088350 Lactate Dehydrogenase 5 Proteins 0.000 claims 13
- 239000012634 fragment Substances 0.000 claims 13
- 229940124597 therapeutic agent Drugs 0.000 claims 13
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 12
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 claims 12
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 claims 12
- 125000001424 substituent group Chemical group 0.000 claims 12
- 125000001624 naphthyl group Chemical group 0.000 claims 11
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 claims 10
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 claims 10
- 230000000694 effects Effects 0.000 claims 9
- 238000002372 labelling Methods 0.000 claims 9
- 239000000651 prodrug Substances 0.000 claims 9
- 229940002612 prodrug Drugs 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 150000001413 amino acids Chemical class 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 8
- 238000003776 cleavage reaction Methods 0.000 claims 8
- 230000007017 scission Effects 0.000 claims 8
- 238000011282 treatment Methods 0.000 claims 8
- OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical group NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 claims 7
- 108010068380 arginylarginine Proteins 0.000 claims 7
- 230000003211 malignant effect Effects 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 238000001959 radiotherapy Methods 0.000 claims 7
- 238000001356 surgical procedure Methods 0.000 claims 7
- AOUOVFRSCMDPFA-QSDJMHMYSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(O)=O AOUOVFRSCMDPFA-QSDJMHMYSA-N 0.000 claims 6
- NQIHMZLGCZNZBN-PXNSSMCTSA-N Trp-Trp Chemical group C1=CC=C2C(C[C@H](NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)N)C(O)=O)=CNC2=C1 NQIHMZLGCZNZBN-PXNSSMCTSA-N 0.000 claims 6
- 235000001014 amino acid Nutrition 0.000 claims 6
- 235000003704 aspartic acid Nutrition 0.000 claims 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 6
- 201000001441 melanoma Diseases 0.000 claims 6
- 108010045269 tryptophyltryptophan Proteins 0.000 claims 6
- 206010006187 Breast cancer Diseases 0.000 claims 5
- 206010018338 Glioma Diseases 0.000 claims 5
- 206010025323 Lymphomas Diseases 0.000 claims 5
- 206010029260 Neuroblastoma Diseases 0.000 claims 5
- 206010033128 Ovarian cancer Diseases 0.000 claims 5
- 206010060862 Prostate cancer Diseases 0.000 claims 5
- 206010039491 Sarcoma Diseases 0.000 claims 5
- 239000002253 acid Substances 0.000 claims 5
- 230000002378 acidificating effect Effects 0.000 claims 5
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 5
- 210000004696 endometrium Anatomy 0.000 claims 5
- 201000004101 esophageal cancer Diseases 0.000 claims 5
- 206010017758 gastric cancer Diseases 0.000 claims 5
- 201000010536 head and neck cancer Diseases 0.000 claims 5
- 208000029824 high grade glioma Diseases 0.000 claims 5
- 208000032839 leukemia Diseases 0.000 claims 5
- 208000029565 malignant colon neoplasm Diseases 0.000 claims 5
- 201000011614 malignant glioma Diseases 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 5
- 210000000496 pancreas Anatomy 0.000 claims 5
- 239000008024 pharmaceutical diluent Substances 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 5
- 210000002307 prostate Anatomy 0.000 claims 5
- 206010038038 rectal cancer Diseases 0.000 claims 5
- 210000000664 rectum Anatomy 0.000 claims 5
- 238000011269 treatment regimen Methods 0.000 claims 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims 5
- 239000000556 agonist Substances 0.000 claims 4
- 201000010881 cervical cancer Diseases 0.000 claims 4
- 210000004072 lung Anatomy 0.000 claims 4
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical group C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims 4
- MJIDYLIDXWGFRN-QMMMGPOBSA-N (2s)-2-[2-(diaminomethylidene)hydrazinyl]-3-phenylpropanoic acid Chemical compound NC(=N)NN[C@H](C(O)=O)CC1=CC=CC=C1 MJIDYLIDXWGFRN-QMMMGPOBSA-N 0.000 claims 3
- NNWQLZWAZSJGLY-VKHMYHEASA-N (2s)-2-azaniumyl-4-azidobutanoate Chemical compound OC(=O)[C@@H](N)CCN=[N+]=[N-] NNWQLZWAZSJGLY-VKHMYHEASA-N 0.000 claims 3
- JASNXOXPNZWQRV-UHFFFAOYSA-N 3-azaniumyl-3-naphthalen-2-ylpropanoate Chemical compound C1=CC=CC2=CC(C(CC(O)=O)N)=CC=C21 JASNXOXPNZWQRV-UHFFFAOYSA-N 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims 3
- 238000004458 analytical method Methods 0.000 claims 3
- 238000001514 detection method Methods 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 230000001394 metastastic effect Effects 0.000 claims 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims 3
- HOKKHZGPKSLGJE-VKHMYHEASA-N (2s)-2-(methylamino)butanedioic acid Chemical group CN[C@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-VKHMYHEASA-N 0.000 claims 2
- 102000011727 Caspases Human genes 0.000 claims 2
- 108010076667 Caspases Proteins 0.000 claims 2
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 claims 2
- 108010033276 Peptide Fragments Proteins 0.000 claims 2
- 102000007079 Peptide Fragments Human genes 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 239000007850 fluorescent dye Substances 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 125000000542 sulfonic acid group Chemical group 0.000 claims 2
- 238000001262 western blot Methods 0.000 claims 2
- SGFJAJFBGVAOFW-UHFFFAOYSA-N 2-[[4-[4-[[3-[(2-methyl-1,3-benzothiazol-6-yl)amino]-3-oxopropyl]amino]-4-oxobutyl]phenyl]methyl]propanedioic acid Chemical compound C1=C2SC(C)=NC2=CC=C1NC(=O)CCNC(=O)CCCC1=CC=C(CC(C(O)=O)C(O)=O)C=C1 SGFJAJFBGVAOFW-UHFFFAOYSA-N 0.000 claims 1
- 102000003952 Caspase 3 Human genes 0.000 claims 1
- 108090000397 Caspase 3 Proteins 0.000 claims 1
- 108010069514 Cyclic Peptides Proteins 0.000 claims 1
- 102000001189 Cyclic Peptides Human genes 0.000 claims 1
- 229940122261 Lactate dehydrogenase A inhibitor Drugs 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 125000000129 anionic group Chemical group 0.000 claims 1
- 150000001450 anions Chemical group 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 230000002860 competitive effect Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 208000000649 small cell carcinoma Diseases 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1077—Pentosyltransferases (2.4.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/02—Pentosyltransferases (2.4.2)
- C12Y204/0203—NAD+ ADP-ribosyltransferase (2.4.2.30), i.e. tankyrase or poly(ADP-ribose) polymerase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
- Oncology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1413942.2A GB2530479A (en) | 2014-08-06 | 2014-08-06 | Peptides useful for treating cancer |
| GB1413942.2 | 2014-08-06 | ||
| PCT/EP2015/068056 WO2016020437A1 (en) | 2014-08-06 | 2015-08-05 | Peptides useful for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017106945A true RU2017106945A (ru) | 2018-09-06 |
| RU2017106945A3 RU2017106945A3 (enExample) | 2019-03-28 |
Family
ID=51587828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017106945A RU2017106945A (ru) | 2014-08-06 | 2015-08-05 | Пептиды, применимые для лечения злокачественной опухоли |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20170313746A1 (enExample) |
| EP (1) | EP3177716A1 (enExample) |
| JP (1) | JP2017529386A (enExample) |
| CN (1) | CN107406485A (enExample) |
| AU (1) | AU2015299032A1 (enExample) |
| CA (1) | CA2960070A1 (enExample) |
| GB (1) | GB2530479A (enExample) |
| RU (1) | RU2017106945A (enExample) |
| WO (1) | WO2016020437A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017066454A2 (en) | 2015-10-14 | 2017-04-20 | X-Therma, Inc. | Compositions and methods for reducing ice crystal formation |
| GB201602409D0 (en) * | 2016-02-10 | 2016-03-23 | Warenius Hilmar M | Compositions and uses thereof |
| GB2582571B (en) | 2019-03-25 | 2024-02-28 | Syntherix Ltd | Peptides and use thereof |
| CN113109418B (zh) * | 2021-04-21 | 2022-09-09 | 苏州大学 | 一种己糖激酶2抑制剂的筛选方法和小分子化合物在制备抗肿瘤药物中的应用 |
| GB2628421A (en) | 2023-03-24 | 2024-09-25 | Syntherix Ltd | Peptides and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1349555A4 (en) * | 2000-12-04 | 2007-04-25 | Sloan Kettering Inst Cancer | TREATMENT OF CANCER BY REDUCING INTRACELLULAR ENERGY AND USING PYRIMIDINES |
| WO2003004600A2 (en) * | 2001-07-05 | 2003-01-16 | Yale University | Improvement of viral uptake into cells and tissues |
| US7439031B2 (en) * | 2003-12-15 | 2008-10-21 | The Trustees Of The University Of Pennsylvania | Method of identifying compounds that induce cell death by necrosis |
| GB0804496D0 (en) * | 2008-03-11 | 2008-04-16 | Theryte Ltd | Treating cancer |
| CA2878094A1 (en) * | 2012-06-27 | 2014-01-03 | Siscapa Assay Technologies, Inc. | Multipurpose mass spectrometric assay panels for peptides |
| WO2014053879A1 (en) * | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| DK3456734T3 (da) * | 2012-10-04 | 2022-04-19 | Res Found Dev | Serinproteasemolekyler og behandlinger |
-
2014
- 2014-08-06 GB GB1413942.2A patent/GB2530479A/en not_active Withdrawn
-
2015
- 2015-08-05 EP EP15745496.8A patent/EP3177716A1/en not_active Withdrawn
- 2015-08-05 JP JP2017526762A patent/JP2017529386A/ja active Pending
- 2015-08-05 RU RU2017106945A patent/RU2017106945A/ru not_active Application Discontinuation
- 2015-08-05 US US15/501,748 patent/US20170313746A1/en not_active Abandoned
- 2015-08-05 WO PCT/EP2015/068056 patent/WO2016020437A1/en not_active Ceased
- 2015-08-05 AU AU2015299032A patent/AU2015299032A1/en not_active Abandoned
- 2015-08-05 CA CA2960070A patent/CA2960070A1/en not_active Abandoned
- 2015-08-05 CN CN201580054152.2A patent/CN107406485A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015299032A1 (en) | 2017-03-23 |
| US20170313746A1 (en) | 2017-11-02 |
| RU2017106945A3 (enExample) | 2019-03-28 |
| CN107406485A (zh) | 2017-11-28 |
| EP3177716A1 (en) | 2017-06-14 |
| GB201413942D0 (en) | 2014-09-17 |
| GB2530479A (en) | 2016-03-30 |
| CA2960070A1 (en) | 2016-02-11 |
| WO2016020437A1 (en) | 2016-02-11 |
| JP2017529386A (ja) | 2017-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230212549A1 (en) | Compounds comprising a fibroblast activation protein ligand and use thereof | |
| US20240115745A1 (en) | Compounds comprising a fibroblast activation protein ligand and use thereof | |
| RU2017106945A (ru) | Пептиды, применимые для лечения злокачественной опухоли | |
| WO2022017375A1 (zh) | 一种FAP-α特异性肿瘤诊断SPECT显像剂 | |
| US20220315554A1 (en) | Compounds comprising a fibroblast activation protein ligand and use thereof | |
| Miao et al. | In vivo evaluation of 188Re‐labeled alpha‐melanocyte stimulating hormone peptide analogs for melanoma therapy | |
| ES2729555T3 (es) | Inhibidores homomultivalentes y heteromultivalentes de antígeno de membrana específico de próstata (PMSA) y usos de los mismos | |
| IL320543A (en) | Compounds comprising a fibroblast activation protein ligand and use thereof | |
| JP7667765B2 (ja) | がんイメージング及びがん放射線治療のための組成物及び方法 | |
| CN111065646A (zh) | 放射性药物 | |
| JP2022507296A (ja) | ガストリン放出ペプチド受容体（ｇｒｐｒ）のインビボイメージングおよびｇｒｐｒ関連障害の治療のための放射性標識ボンベシン由来化合物 | |
| EP3763726A1 (en) | Compounds comprising a fibroblast activation protein ligand and use thereof | |
| Shetty et al. | Development of a bifunctional chelating agent containing isothiocyanate residue for one step F-18 labeling of peptides and application for RGD labeling | |
| Flook et al. | Substitution of the Lys linker with the β-Ala linker dramatically decreased the renal uptake of 99mTc-labeled Arg-X-Asp-conjugated and X-Ala-Asp-conjugated α-melanocyte stimulating hormone peptides | |
| WO2023133645A1 (en) | Radiolabeled compounds for imaging of fibroblast activation protein (fap) and treatment of fap-related disorders | |
| WO2024016071A1 (en) | Radiolabeled compounds targeting the prostate-specific membrane antigen | |
| KR20230092906A (ko) | 신규한 cxcr4 표적화 화합물 | |
| JPH04500805A (ja) | 標的剤 | |
| Yang et al. | Tc-99m-labeled RGD-conjugated alpha-melanocyte stimulating hormone hybrid peptides with reduced renal uptake | |
| Sano et al. | A radiogallium–DOTA-based bivalent peptidic ligand targeting a chemokine receptor, CXCR4, for tumor imaging | |
| RU2018131821A (ru) | Композиции и их применения | |
| US11077217B2 (en) | Radioactive labeling method for neuropeptide Y derivative compound and medicine for multi-type breast cancer therapy thereof | |
| WO2018226971A1 (en) | Peptide compositions for immuno-oncology molecular imaging and targeted drug delivery | |
| Chen et al. | A Novel 68Ga‐Labeled 2‐Azabicyclo [3.1. 0] Hexane‐3‐Carbonitrile‐Based Fibroblast Activation Protein‐Targeted Tracer for Cancer Imaging With Positron Emission Tomography | |
| WO2025059775A1 (en) | Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20210219 |